Obermatt
See Similar Stocks →

Flags

Financial distress

BRAIN Biotech

GER:BNN · DE0005203947
ChemicalsSmall

360

40
Profit price79
Owner Earnings Yield1
Dividend Yield1
Price/Sales80
EV / Gross Profit81
Price/Book97
Returns on capital1
EBIT Margin8
Gross Profitability94
Accruals73
Owner Earnings Margin10
Sales growth69
Profit Growth30
Long-Term EPS Growth1
Reinvestment6
Price momentum85
Debt load1
Refinancing67
Debt Payback1
Liquidity23
Analyst ratings100
Opinion Changes50
Price Target Upside97
Market mood87
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

BRAIN Biotech doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryGermany
IndustryChemicals
SizeSmall
TypePublic Company
ExchangeXTRA
Employees66
Websitebrain-biotech.com/de
ISINDE0005203947
Last UpdateApr 2, 2026
Indices
CDAX (Germany)
Themes
AgriTechAnimal FeedBio-based and Renewable MaterialsGeneticsBiotechnologyChemicalFood and BeveragePharmaceutical

Description

BRAIN Biotech AG engages in the research and development of Bio-based products and solutions. Business Segments The company operates through three business segments: BioProducts, BioScience, and BioIncubator. BioProducts This segment focuses prim…

Analysis

Middle-of-the-road

BRAIN Biotech AG is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 0/20 on our value-creation score: not creating value. Analysts lean positive.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
56
2023202420252026

All-time high

59

Mar 2026

All-time low

7

Jan 2025

Average rank

29

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
80
73
64
39
Price/Earnings
81
3
26
29
Price/Book
97
20
25
17
Dividend Yield
1
1
1
1
Value (overall)
78
12
29
21

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare BRAIN Biotech with its peers
DSM-Firmenich
AEX:DSFIR
23
CountrySwitzerland
IndustryChemicals
SizeX-Large
Full Stock Analysis →
Novozymes
CPH:NSIS B
45
CountryDenmark
IndustryChemicals
SizeX-Large
Full Stock Analysis →
Symrise
GER:SY1
27
CountryGermany
IndustryChemicals
SizeLarge
Full Stock Analysis →
Corbion
AEX:CRBN
65
CountryNetherlands
IndustryChemicals
SizeMedium
Full Stock Analysis →
Unilever
LSE:ULVR
43
CountryUK
IndustryPersonal Products
SizeXX-Large
Full Stock Analysis →
Adocia
PAR:ADOC
63
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →